MG132 dramatically reduces SAA expression in chicken hepatocellular carcinoma cells at the transcript level independent of its endogenous promoter

Nora-Fabienne Paul,Karolin Gustmann,Jens Tetens,Clemens Falker-Gieske
DOI: https://doi.org/10.1007/s11033-024-09726-9
IF: 2.7422
2024-06-20
Molecular Biology Reports
Abstract:MG132, a proteasome inhibitor, is widely used to inhibit nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activity by proteasome-mediated degradation of IκB. It has been marketed as a specific, reversible, cell-permeable and low-cost inhibitor. However, adverse effects of the compound have been reported in the literature. We recently discovered and characterised a point mutation in the acute phase protein serum amyloid A (SAA) in chickens, by overexpressing the protein in chicken hepatocellular carcinoma (LMH) cells. This serine to arginine exchange at amino acid position 90 (SAA.R90S) leads to intra- and extracellular accumulation of SAA, which is surprisingly counteracted by MG132 treatment, independent of SAA 's intrinsic promoter.
biochemistry & molecular biology
What problem does this paper attempt to address?